Frey AB - Search Results

1

Protocadherin-18 is a novel differentiation marker and an inhibitory signaling receptor for CD8+ effector memory T cells.

Vazquez-Cintron EJ, Monu NR, Burns JC, Blum R, Chen G, Lopez P, Ma J, Radoja S, Frey AB. Vazquez-Cintron EJ, et al. Among authors: frey ab. PLoS One. 2012;7(5):e36101. doi: 10.1371/journal.pone.0036101. Epub 2012 May 2. PLoS One. 2012. PMID: 22567129 Free PMC article.

2

Suppression of proximal T cell receptor signaling and lytic function in CD8+ tumor-infiltrating T cells.

Monu N, Frey AB. Monu N, et al. Among authors: frey ab. Cancer Res. 2007 Dec 1;67(23):11447-54. doi: 10.1158/0008-5472.CAN-07-1441. Cancer Res. 2007. PMID: 18056473 Free PMC article.

3

Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase.

Vazquez-Cintron EJ, Monu NR, Frey AB. Vazquez-Cintron EJ, et al. Among authors: frey ab. J Immunol. 2010 Dec 15;185(12):7133-40. doi: 10.4049/jimmunol.1001157. J Immunol. 2010. PMID: 21127315 Free PMC article. Review.

4

Myeloid-derived suppressor cells and anti-tumor T cells: a complex relationship.

Monu NR, Frey AB. Monu NR, et al. Among authors: frey ab. Immunol Invest. 2012;41(6-7):595-613. doi: 10.3109/08820139.2012.673191. Immunol Invest. 2012. PMID: 23017137 Free PMC article. Review.

5

Defective proximal TCR signaling inhibits CD8+ tumor-infiltrating lymphocyte lytic function.

Koneru M, Schaer D, Monu N, Ayala A, Frey AB. Koneru M, et al. Among authors: frey ab. J Immunol. 2005 Feb 15;174(4):1830-40. doi: 10.4049/jimmunol.174.4.1830. J Immunol. 2005. PMID: 15699109

6

Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response.

Frey AB, Monu N. Frey AB, et al. J Leukoc Biol. 2006 Apr;79(4):652-62. doi: 10.1189/jlb.1105628. Epub 2006 Jan 13. J Leukoc Biol. 2006. PMID: 16415165 Review.

7

Defective adhesion in tumor infiltrating CD8+ T cells.

Koneru M, Monu N, Schaer D, Barletta J, Frey AB. Koneru M, et al. Among authors: frey ab. J Immunol. 2006 May 15;176(10):6103-11. doi: 10.4049/jimmunol.176.10.6103. J Immunol. 2006. PMID: 16670319

8

Signaling defects in anti-tumor T cells.

Frey AB, Monu N. Frey AB, et al. Immunol Rev. 2008 Apr;222:192-205. doi: 10.1111/j.1600-065X.2008.00606.x. Immunol Rev. 2008. PMID: 18364003 Free PMC article. Review.

9

Cancer-induced defective cytotoxic T lymphocyte effector function: another mechanism how antigenic tumors escape immune-mediated killing.

Radoja S, Frey AB. Radoja S, et al. Among authors: frey ab. Mol Med. 2000 Jun;6(6):465-79. Mol Med. 2000. PMID: 10972084 Free PMC article. Review.

10

CD8+ tumor-infiltrating lymphocytes are primed for Fas-mediated activation-induced cell death but are not apoptotic in situ.

Radoja S, Saio M, Frey AB. Radoja S, et al. Among authors: frey ab. J Immunol. 2001 May 15;166(10):6074-83. doi: 10.4049/jimmunol.166.10.6074. J Immunol. 2001. PMID: 11342625

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

90 results

Search Page

Filters